Clarivate Plc has announced the release of the 2020 Centre for Medicines Research (CMR) International Pharmaceutical Clinical Factbook. The factbook reveals clinical trial volume has increased by 7% between 2014 and 2019 with Phase II trials accounting for the majority of trials initiated during the period. The report finds the number of Phase I and II trials have shown a slight decrease between 2015 and 2019, while Phase III has seen a slight increase. The overall duration for Phase II and III trials is comparable.
The Center for Medicines Research, a wholly owned subsidiary of Clarivate, has released the report to help pharmaceutical and biotechnology companies benchmark their clinical strategy against industry standards and competitors. The annual publication provides insights on clinical study, country and site level metrics from Phase I through Phase IV.
Learn more in the full release, here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.